Current therapies for lysosomal storage diseases (LSDs), enzyme replacement therapy and bone marrow transplantation are effective for visceral organ pathology of LSD, but their effectiveness for brain involvement in LSDs is still a subject of controversy. As an alternative approach, we transplanted genetically modified bone marrow stromal (BMS) cells to lateral ventricle of newborn mucopolysaccharidosis VII (MPS VII) mice. MPS VII is one of LSDs and caused by deficiency of beta-glucuronidase (GUSB), resulting in accumulation of glycosaminoglycans (GAGs) in brain. At 2 weeks after transplantation, the GUSB enzyme-positive cells were identified in olfactory bulb, striatum and cerebral cortex, and the enzymatic activities in various brain areas increased. The GAGs contents in brain were reduced to near normal level at 4 weeks after transplantation. Although GUSB activity declined to homozygous level after 8 weeks, the reduction of GAGs persisted for 16 weeks. Microscopic examination indicated that the lysosomal distention was not found in treated animal brain. Cognitive function in MPS VII animals as evaluated by Morris Water Maze test in treated mice showed a marked improvement over nontreated animals. Brain transplantation of genetically modified BMS cells appears to be a promising approach to treat diffuse CNS involvement of LSDs.
Introduction
Mucopolysaccharidosis type VII (MPS VII, Sly syndrome) is one of lysosomal storage diseases (LSDs) caused by deficiency of beta-glucuronidase (GUSB), resulting in progressive accumulation of undegraded glycosaminoglycans (GAGs) in various tissues including the brain. 1, 2 A murine model of MPS VII is available and its clinical, biochemical and pathological features closely reflect those of human MPS VII. [3] [4] [5] Using this mouse model, various therapeutic approaches including enzyme replacement therapy, [6] [7] [8] bone marrow transplantation (BMT), [9] [10] [11] gene therapy [12] [13] [14] and cell therapy [15] [16] [17] have previously been attempted with varying degree of success. In case of enzyme replacement therapy, patients must continue to receive enzyme replacement in their whole life and the cost of recombinant enzyme is another big burden to patients. BMT results in high mortality and morbidity rate, especially at early infancy. In gene therapy, although AAV vectors appear to have a promise, it is still difficult to produce large amount of recombinant virus. The safety issue of lentivirus vector is another major concern for use of this virus vector to human. In cell therapy, although transplantation of neural stem cells or amniotic cells shows a great hope to treat CNS involvement in MPS VII, ethical and immunologic problems must be cleared. Recent studies have demonstrated that the bone marrow stromal (BMS) cells have ability to differentiate into osteocytes, chondrocytes, adipocytes, muscle and also into neural cells, [18] [19] [20] [21] [22] and that the brain transplantation of BMS cells induces good clinical outcome in neurological diseases such as brain infarction 23 and LSD. 24 Patient's BMS cells could be harvested by a simple bone marrow aspiration and grow rapidly in culture, and autologous transplantation can overcome ethical and immunologic problems associated with transplantation of neural stem cells or amniotic cells. In the present study, we demonstrate that the intraventricular transplantation of BMS cells overexpressing GUSB in neonatal MPS VII mice corrects the CNS pathology and function in these mutant mice.
Results
Transduction of KUSA/A1 by MND/HBG KUSA/A1, mouse bone marrow stromal cell, was transduced with human GUSB gene by retrovirus vector. The GUSB activity in transduced cell (KUSA/HBG) was increased from 5.9 Â 10 1 to 1.9 Â 10 6 nmol/h/mg. Histochemical staining of GUSB-bearing KUSA/HBG cells exhibited positive staining for GUSB, while parental KUSA/A1 cells were negative for the staining (data not shown). These results are consistent with the data of enzymatic activity.
Distribution of GUSB activity in the brain after transplantation
At 2 and 8 weeks after transplantation, GUSB activities in the recipient brains were determined. Serial coronal sections of mouse brain as shown in Figure 1 were collected and GUSB activity was assayed quantitatively in each section. GUSB activity in all brain regions of treated MPS VII mice 2 weeks after transplantation was higher than in those of age-matched untreated MPS VII mice ( Figure 1 ). GUSB activity of treated MPS VII mouse brain was approximately 50 times higher than that of untreated MPSVII mice in each section. This value corresponds to approximately 20% of heterozygote mouse level. At 8 weeks after transplantation, GUSB activity in treated mouse brain declined to homozygote mouse level.
Biochemical response of the brain in treated MPS VII mice
It has been known that the enzyme activity of other lysosomal enzymes such as a-galactosidase A (a-Gal) and hexosaminidase (Hex) are elevated in MPS VII mouse brain, and that the reduction of these enzymes by treatment is well correlated with therapeutic effect. [8] [9] [10] Thus, to monitor the therapeutic effect of cell transplantation, we assayed enzyme activities of a-Gal and Hex in the brain of mice at 2 weeks after transplantation. Activities of both enzymes in the treated mouse brain decreased to those of heterozygous mouse level (Figure 2a, b) .
Histochemical detection of GUSB-positive cells in treated mouse brain
At 2 weeks after transplantation, we examined the survival and distribution of transplanted cells by GUSB histochemical analysis. In transplanted mice GUSB positive cells (red) were found not only in meninges and subventricular regions (Figure 3a ) but also in Figure 1 GUSB activity in various regions of the brain after transplantation. Average of GUSB activity in various regions of the brain of mice at 2 (n ¼ 2) and 8 (n ¼ 3) weeks after transplantation and age-matched untreated mutant mice. Mouse brains were divided into serial five coronal sections. The regions were defined by anatomical landmark: a, olfactory bulb; b, from end of olfactory bulb to beginning of striatum; c, striatum to the rostal edge of the hippocampus; d, hippocampus to colliculus and midbrain; e, cerebellum and brain stem. GUSB activity was expressed as nmol/h/mg protein. 
Reduction in levels of GAGs in the brain of treated MPS VII mice
Levels of GAGs in the brain were determined in treated MPS VII mice at 4, 8, 16 weeks after transplantation (Table 1) . In this study, we assayed amount of total chondroitin sulfate (T-CS) and hyaluronic acid (HA), which are known to accumulate in the MPS VII brain. At 4 weeks after transplantation, both of these two GAGs in treated MPS VII mice were reduced significantly as compared to age-matched untreated MPS VII mice (T-CS; P ¼ 0.0012, HA; P ¼ 0.0002 respectively). Although the enzymatic activity diminished to homozygous level 8 weeks after transplantation, a significant reduction (T-CS; P ¼ 0.0071, HA; P ¼ 0.0001) of GAGs in the brain of treated MPS VII mice persisted up to 16 weeks after treatment.
Improvement of cognitive function with the Morris Water Maze (MWM) test
We performed the visible test before nonvisible test and there was no significant difference of normal mice and untreated MPS VII mice at 6 weeks old (data not shown). These data indicate that there is no significant difference of motor function between wild-type mouse and mutant mouse. At 6 weeks after transplantation, we performed the MWM to evaluate improvement of cognitive function by the treatment. Mice were adapted to the pool at the day before the acquisition phase. The acquisition phase: All of mice were trained from day 1 to day 5 to memorize the platform place. The probe test ( Figure 5 ): The probe test was performed on day 6, immediately after the acquisition phase. The platform was removed and the amount of time spent in each quadrant was monitored. It is well known that normal mice spend longer time in target quadrant where the platform was placed at the acquisition phase than the mean of other three nontarget quadrants. Average of the time spent in the target quadrant by treated mice was 22.4 (s), whereas average of the time spent by untreated mice was 18.2 (s). Treated MPS VII mice spent significantly more time in the target quadrant than in the mean of other three nontarget quadrants (P ¼ 0.0028), whereas in untreated MPS VII mice the difference of time spent in the target quadrant and the mean of the other three nontarget quadrants was not statistically significant (P ¼ 0.3201).
Discussion
Current available therapies for LSDs are BMT and enzyme replacement therapy. However, both approaches have inherent problems. BMT has high mortality and morbidity rate and enzyme replacement therapy has economic problems and life-long infusion of enzyme In the present study, we tested BMS cells as a vehicle to deliver the missing enzyme to wide region of the brain of LSD mouse model. The BMS cells have several advantages as compared to other stem/progenitor cells. First, the BMS cells are readily accessible from bone marrow and grow well in vitro. Second, the autologous transplantation overcomes the ethical and immunologic concerns. BMS cells have capability to differentiate into various neural cell lineages. We generated GUSB overexpressing BMS cell (KUSA/HBG) and KUSA/HBG was transplanted into lateral ventricle of newborn MPS VII mice. At 2 weeks after transplantation, expression of GUSB was observed in all of brain lesions. GUSB histochemical staining revealed that transplanted cells migrated to various brain regions not only ventricles also brain parenchyma, including cerebral cortex and olfactory bulb. Even though the number of transplanted cells in brain parenchyma was small, the pathological improvement is significant. Lysosomal storage in most of cells, such as endothelial cells, glial cells and neurons from various brain regions, was reduced. The amount of T-CS and HA, which was accumulated GAGs in MPS VII brain, was also reduced markedly.
To assess the functional improvement of the treated animals, we performed the MWM testThe MWM is known as test to evaluate cognitive functions. At 6 weeks after the transplantation, treated MPS VII mice spent significantly more time in the target quadrant than in the other three nontarget quadrants and the time spent in the target quadrant by treated MPS VII increased compared with by untreated MPS VII mice. Earlier report also demonstrated that the enzyme replacement therapy in neonatal period, 7 gene therapy using lentivirus vector 14 successfully restored brain function of MPS II mice. The expression of GUSB in the brain of treated animals 8 weeks after transplantation was markedly reduced. This relatively early reduction of GUSB activity in transplanted cells might be due to a mismatched allograft transplantation. KUSA/A1 cells are derived from C3H mouse, while MPS VII mice are C57BL/6 background. In addition, because KUSA/HBG expresses huge amount of human enzyme and the mouse immune system might recognize transplanted cell as a foreign cells. Thus, there is a possibility that transplanted cells were rejected by immunological mechanisms. Another possibility is that the transplanted cells underwent apoptosis from other unspecified mechanisms. We previously transplanted human neural stem cells into lateral ventricle of newborn MPS VII mice. 16 The human neural cells transduced with GUSB gene successfully corrected CNS pathology and restored enzyme levels, but grafted cells later underwent cell death by apoptosis mechanisms. The experiment is currently under way to understand the mechanism(s) for early death of KUSA/HBG cells in mouse brain. In the present study, although GUSB activity of treated mice 8 weeks after transplantation declined to those of untreated mice, interestingly, the restored GAGs contents in treated mouse brain were maintained up to 16 weeks after transplantation. Moreover the MWM showed that the brain function of treated mice still improved.
These results suggest that once MPS VII mice receive certain amount of GUSB cells in early stage, the brain function was maintained even after the considerable reduction of enzymatic activity. GAGs synthesis and GAGs turn over in adult MPS VII brain may be small so that GAGs do not re-accumulate. Large amount of GUSB may not be necessary for adult MPS VII brain after newborn brain treatment with GUSB.
Another question is what kinds of cell types transplanted cells differentiate into following brain transplantation. Previous reports have shown that the marrow stromal cells transplanted into the brain migrate to the parenchyma and differentiate into neural cells.
21,22
Number of KUSA/HBG cells in brain parenchyma was too small to perform double immunostaining, thus we performed another set of experiments. Briefly, KUSA/A1 cells were transduced by a LacZ expressing retrovirus vector and transplanted into striatum of adult C57BL/6 mice. After transplantation, frozen sections were made and double stained with anti-LacZ antibody and cell 25 In this regard, even if transplanted BMS cells did not differentiate into neural cells, BMS cell transplantation can correct the brain involvement of MPS VII. There are still some obstacles to be overcome to use BMS cell as a vehicle for treatment of brain involvement of LSDs. We transplanted BMS cells during neonatal period. However, it is quite rare that LSDs patients were diagnosed in this period. The development of newborn screening system for early detection of LSDs patients may overcome this problem. We do not know if BMS cell transplantation should have beneficial effect for the CNS involvement in MPS VII in later stage. Since a previous study has demonstrated that the BMS cell brain transplantation in Niemann-Pick disease mice at 3 weeks of age was effective for CNS involvement, 24 this may be the case for MPS VII as well. The transplantation of BMS cell into the brain in MPS mice at 3-4 weeks of age is underway.
In conclusion, we have demonstrated that the intraventricular transplantation of BMS cells overexpressing GUSB in neonatal MPS VII mice corrects the biochemical defects, CNS pathology and cognitive behavior in these mutant mice.
Materials and methods

Animals
Breeding pairs of (+/mps) were purchased form the Jackson Laboratory and bred in our institutional animal facility. Mutant mice (À/À) were identified by genetic analysis of DNA from mouse tail. 26 Enzymatic activity of tail was also measured as described below to confirm the diagnosis. Animals were maintained on a 12-h light/ dark cycle and given a standard rodent chow.
BMS cell
Mouse BMS cell line, KUSA/A1, was established by limiting dilution of Dexter long-term cultures from C3H/ He female mouse. The detailed methods and characters of this cell line were described previously. 20 This cell line is able to differentiate into osteoblasts and neural cells, including neurons, astrocytes and oligodendrocytes under specific conditions. This cell line was cultivated in DMEM/10% FCS at 371C and 5% CO 2 .
In vitro retroviral transduction
Full-length human GUSB cDNA (provided by Dr WS Sly of Saint Louis University) was cloned into EcoRI site of retrovirus vector plasmid pMNDXSN (provided by Dr DB Kohn of University Southern California). 27 The recombinant retrovirus expressing human GUSB was generated by transfection of this plasmid to PA317 packaging lines. The condition medium of packaging cells were collected and filtered through 0.45 mm filter. The resultant condition medium was added to B50% confluent KUSA/A1 cells and incubated at 371C for 2 h in the presence of polybrene (8 mg/ml). After incubation, the condition medium was removed and fresh medium (DMEM/10% FCS) was added. About 24 h later, the cells were selected with G418 (400 mg/ml) and resistant cells were pooled (KUSA/HBG). The GUSB activity in KUSA/HBG was assayed as described below to confirm successful transduction. Cytochemical analysis of GUSB was also performed. .
Histochemical/cytochemical analysis of GUSB Transplanted mice were killed at 2 weeks after transplantation. Brain was removed and immediately embedded with OCT compound (Miles) and frozen in a liquid nitrogen bath. The samples were cut 10 mm sections by cryostat. The sections were fixed with chloralformal-acetone fixative. The histochemical analysis of GUSB activity was performed using naphthol-AS-BI b-D-glucuronide as a substrate. The detail method of this staining was described elsewhere. 26 After hisitochemical staining of GUSB, sections were counterstained with 1% methyl green. The culture cells were fixed and stained with same method as stated above.
Lysosomal enzymes activities
Cells were washed briefly with PBS twice and harvested by 0.1% trypsin. After centrifugation, cell pellets were stocked at À801C until assay. Cell pellets were resuspended in water and sonicated. The cell lysate was centrifuged at 14 000 g for 10 min at 41C. The treated mice, age-matched mutant (À/À) and heterozygote (+/À) mice were killed at 2 and 8 weeks after transplantation. Harvested mouse brains were also stocked at À801C until assay. To assess the distribution of transplanted cells, brain was cut into five serial coronal sections (Figure 1 ). To make tissue lysate, tissue was homogenized in water using a glass homogenizer. The homogenates were also centrifuged at 14 000 g for 10 min at 41C and the resultant supernatant was used as enzyme source. The enzymatic activities of GUSB, a-Gal and Hex were measured fluorometrically using the artificial substrate, 4-methylumbelliferyl (4MU) b-Dglucuronide, 4MU a-D-galactopyranoside and 4MU N-acetyl-b-D-glucosaminide dihydrate (Sigma) respectively. 26, 29, 30 Protein concentration was determined by the BCA kit (Pierce) following the manufacture's instruction. Activity was expressed as nanomoles of 4-methylumbelliferone released per mg protein per hour.
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Histopathological analysis of lysosomal distension
At 4 weeks after transplantation, treated mice, agematched mutant and heterozygote mice were killed. Small blocks (3 Â 3 Â 3 mm 3 ) of various brain regions (olfactory bulb, cerebral cortex, and striatum) were immersed in 2% glutaraldehyde in PBS and fixed for 2-3 weeks. After fixation, the samples were embedded in Epon-araldite. Ultrathin sections (1.0 mm) were cut and were stained with toluidine blue to evaluate lysosomal distention.
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Analysis of GAG contents
Brain contents of T-CS and HA, which is substrate of GUSB, were measured by enzyme digestion and HPLC method. 31 The amount of T-CS and HA were expressed as mg/g wet tissue.
The MWM test
The MWM test was carried out at 6 weeks after transplantation. The acquisition phase and the probe test of the MWM test were performed as previously described. 32, 33 The MWM test was slightly modified for this test. Briefly, the pool of a diameter 100 cm was filled 30 cm deep with water at 201C. A transparent circular plexiglass platform 10 cm in a diameter was placed 1 cm below the surface of the water and 20 cm from the wall of the pool. The pool was designed as divided into four quadrants. The mice were released to the pool facing the wall at three points, four trials per a day were made for each mouse and the order of the releasing points was selected at random but all mice were followed the same order. If the mouse found the platform within 60 s, it was allowed to stay on the platform for 15 s. If the mouse could not find the platform within 60 s, it was guided to the platform by experimenter and it was allowed to stay on the platform for 15 s. All of the mouse traces were recorded by the over-head video camera. The acquisition phase of the test was performed for the 5 consecutive days (days 1-5). On day 6, the platform was removed and mice were released from the opposite side of the original platform place and the amount of time spent in each quadrant was monitored (the probe test).
Statistical analysis
A two-tailed Student's t-test was used for comparing the significance. The data are presented as mean7s.e. P-value less than 0.05 was considered as significant.
